Breaking News Instant updates and real-time market news.

WMT

Walmart

$97.50

0.33 (0.34%)

, KR

Kroger

$24.45

0.01 (0.04%)

09:55
03/29/19
03/29
09:55
03/29/19
09:55

UBS retail analyst to hold an analyst/industry conference call

Retail Analyst Lasser discusses the emerging trends in the grocery industry on an Analyst/Industry conference call to be held on March 29 at 11 am.

WMT

Walmart

$97.50

0.33 (0.34%)

KR

Kroger

$24.45

0.01 (0.04%)

COST

Costco

$241.45

0.145 (0.06%)

TGT

Target

$80.18

-0.14 (-0.17%)

SFM

Sprouts Farmers Market

$21.80

0.08 (0.37%)

  • 29

    Mar

  • 16

    Apr

  • 16

    Apr

  • 16

    May

  • 16

    May

  • 30

    May

WMT Walmart
$97.50

0.33 (0.34%)

03/26/19
CHLM
03/26/19
NO CHANGE
Target $115
CHLM
Buy
Apple Card could mean $100M revenue opportunity for Green Dot, says Craig-Hallum
Craig-Hallum analyst Brad Berning says that details in Apple's (AAPL) Apple Card announcement point to better utilization of Apple Cash, a program powered by Green Dot (GDOT). The analyst believes this could be a $100M annual revenue opportunity over time for Green Dot. Berning adds that while this does not eliminate the market's concerns over a Walmart (WMT) renewal, which he continues to believe will most likely happen, it does highlight his view that there will be numerous potential partnership opportunities for Green Dot over time to win as the leading BaaS arms dealer "for the deposit wars ahead." The analyst reiterates a Buy rating and a $115 price target on Green Dot's shares.
03/25/19
CHLM
03/25/19
NO CHANGE
Target $115
CHLM
Buy
Apple Card could be $100M revenue opportunity for Green Dot, says Craig-Hallum
After Apple (AAPL) announced a new credit card earlier today, Craig-Hallum analyst Brad Berning noted that Green Dot (GDOT) powers Apple Pay Cash. If adoption rates for Apple Card follow Apple Pay's path, Apple Card could equate to a $100M potential annual gross revenue opportunity for Green Dot, Berning tells investors. The Apple Card news will not eliminate the market's concerns over the Walmart (WMT) renewal, but his view is that there will be numerous potential partnership opportunities for Green Dot to win over time, added Berning. He keeps a Buy rating on Green Dot shares with a $115 price target.
03/22/19
UBSW
03/22/19
NO CHANGE
Target $280
UBSW
Buy
Costco price target raised to $280 from $270 at UBS
UBS analyst Michael Lasser raised his price target on Costco (COST) to $280 and kept his Buy rating as part of his deep dive analysis into warehouse clubs. The analyst says the model "remains relevant" and has a "sturdy place" in the omnichannel world, noting that his survey of 1.5K shoppers shows that consumers are loyal to the concept. Lasser cites 91% of Costco members responding that they are "very or somewhat likely to renew", which outpaces intentions recorded at Sam's Club (WMT) and BJ's (BJ). The analyst further notes that Costco has produced 8 consecutive quarters of mid-single-digit core comp growth, suggesting the company's "leadership in this category".
03/21/19
LOOP
03/21/19
NO CHANGE
Target $102
LOOP
Hold
Walmart grocery sales productivity outperforming supermarkets, says Loop Capital
Loop Capital analyst Andrew Wolf kept his Hold rating and $102 price target on Walmart (WMT), saying the company's U.S. grocery comps outperformed the supermarket chains in 2018 as it has since 2016, even though the gap has narrowed. The analyst notes that Kroger (KR) made the biggest strides last year, and that the company was also the best performer in the 2013-2015 period supermarkets last made strong market share gains. Looking ahead, Wolf says the accelerating food-price inflation anticipated by the USDA could also "bode well for continued further same-store sales acceleration for both Walmart and the grocers in 2019."
KR Kroger
$24.45

0.01 (0.04%)

03/20/19
EVER
03/20/19
INITIATION
Target $27
EVER
In Line
Kroger initiated with an In Line at Evercore ISI
Evercore ISI analyst Michael Montani started Kroger with an In Line rating and $27 base case price target, citing his view that Kroger's efforts to build out its ecosystem are admirable, but it's too soon to expect an "Amazon-esque" flywheel to drive sustainable EBIT growth.
02/08/19
02/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Airlines (AAL) initiated with a Hold at Argus. 2. Walmart (WMT) and Sprouts Farmers Market (SFM) were initiated with a Neutral at Buckingham, while Kroger (KR) was initiated with an Underperform. 3. Wrap Technologies (WRTC) initiated with a Buy at Chardan. 4. nLight (LASR) initiated with a Hold at Craig-Hallum. 5. RA Pharmaceuticals (RARX) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/07/19
BUCK
02/07/19
INITIATION
Target $24
BUCK
Underperform
Kroger initiated with an Underperform at Buckingham
Buckingham analyst Bob Summers started Kroger with an Underperform rating and $24 price target. The company has established an "overly ambitious" goal for fiscal 2020 that entails significant investment, Summers tells investors in a research note. The analyst believes deflation, competitive activity, fuel profitability, and the economic cycle pose risk to the company's EBIT growth.
COST Costco
$241.45

0.145 (0.06%)

03/20/19
EVER
03/20/19
INITIATION
Target $260
EVER
Outperform
Costco initiated with an Outperform at Evercore ISI
Evercore ISI analyst Greg Melich started Costco with an Outperform rating and $260 base case price target. While Costco "faces the Amazon wall of worry," he believes its sticky membership model creates loyalty that can drive sales and profits for years to come.
03/19/19
NOMU
03/19/19
INITIATION
NOMU
Neutral
Costco initiated with a Neutral at Nomura Instinet
Nomura Instinet analyst Simeon Siegel initiated Costco with a Neutral rating and $230 price target, saying that while Costco is "one of the most impressive names in retail," its shares reflect that and are fairly valued.
03/19/19
NOMU
03/19/19
INITIATION
Target $230
NOMU
Neutral
Costco initiated with a Neutral at Nomura Instinet
Nomura Instinet initiated Costco with a Neutral and $230 price target.
TGT Target
$80.18

-0.14 (-0.17%)

03/21/19
GDHS
03/21/19
UPGRADE
GDHS
Buy
Target upgraded to Buy from Accumulate at Gordon Haskett
03/11/19
MSCO
03/11/19
NO CHANGE
Target $67
MSCO
Underweight
Target's planned profit inflection seems unlikely to Morgan Stanley
Contrary to Target pointing to a profit inflection in 2019, Morgan Stanley analyst Simeon Gutman believes the company is closer to an inflection, but not there yet. He thinks gross margin savings from e-commerce fulfillment will underwhelm and cost leverage will not offset higher near-term expenses than the market may be prepared for. While he sees a more tangible bull case emerging around Target's ability to drive strong top-line growth through effective merchandising and drive cost efficiencies, he maintains an Underweight rating on the shares. However, Gutman raised his price target on the retailer's stock to $67 from $60 in the wake of the company's financial community meeting.
03/21/19
GDHS
03/21/19
NO CHANGE
GDHS
Gordon Haskett shakes up retailer rankings with six upgrades, three downgrades
Gordon Haskett analysts Chuck Grom, John Park and Andrew Minora have recalibrated their ratings in broadline and hardline retail with the Q4 earnings season nearly complete, stating that holiday results were mixed with clear winners and losers and that year-to-date sales have been "extremely choppy." The firm's latest macro/consumer survey results suggest that some optimism has resurfaced and they see a scenario where there is a release of significant pent-up demand for the retail group. Within the context of a portfolio approach to the space, the analysts upgraded Target (TGT), Tractor Supply (TSCO), Dollar Tree (DLTR), BJ's Wholesale (BJ) to Buy from Accumulate, upgraded Wayfair (W) and Floor & Decor (FND) to Accumulate from Hold, and downgrade Nordstrom (JWN) and Sprouts Farmers Market (SFM) to Reduce from Hold. The analysts also downgraded Pier 1 Imports (PIR) to Underperform from Hold.
03/20/19
EVER
03/20/19
INITIATION
Target $80
EVER
In Line
Target initiated with an In Line at Evercore ISI
Evercore ISI analyst Greg Melich initiated Target with an In Line rating and $80 base case price target, stating that in the upper $70s, the risk/reward appears balanced. He believes 2019 extends what will likely prove a multi-year margin investment cycle, Melich tells investors.
SFM Sprouts Farmers Market
$21.80

0.08 (0.37%)

03/21/19
GDHS
03/21/19
DOWNGRADE
GDHS
Reduce
Sprouts Farmers Market downgraded to Reduce from Hold at Gordon Haskett
03/27/19
WOLF
03/27/19
DOWNGRADE
WOLF
Peer Perform
Sprouts Farmers Market downgraded to Peer Perform at Wolfe Research

TODAY'S FREE FLY STORIES

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary  »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary  »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary  »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary  »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FTSV

Forty Seven

$14.40

0.23 (1.62%)

15:56
12/08/19
12/08
15:56
12/08/19
15:56
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AQST

Aquestive Therapeutics

$8.02

-0.34 (-4.07%)

15:50
12/08/19
12/08
15:50
12/08/19
15:50
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

APRE

Aprea Therapeutics

$26.20

1.995 (8.24%)

15:23
12/08/19
12/08
15:23
12/08/19
15:23
Conference/Events
Aprea Therapeutics to hold a clinical update meeting »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

15:18
12/08/19
12/08
15:18
12/08/19
15:18
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

13:47
12/08/19
12/08
13:47
12/08/19
13:47
Periodicals
International Flavors in talks to buy DuPont nutrition unit, Bloomberg reports »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

KRYAY

Kerry Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWRF

China Tower

$0.00

(0.00%)

13:40
12/08/19
12/08
13:40
12/08/19
13:40
Upgrade
China Tower rating change at Deutsche Bank »

China Tower upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

13:37
12/08/19
12/08
13:37
12/08/19
13:37
Recommendations
Principia Biopharma analyst commentary at Stifel »

Principia shares have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$50.93

0.495 (0.98%)

12:48
12/08/19
12/08
12:48
12/08/19
12:48
Syndicate
Dycom withdraws senior notes offering due to market conditions »

Dycom Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

IMV

IMV Inc.

$2.92

0.07 (2.46%)

12:30
12/08/19
12/08
12:30
12/08/19
12:30
Hot Stocks
IMV announces updated results from Phase 2 study of DPX-Survivac »

IMV Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$15.67

0.48 (3.16%)

12:27
12/08/19
12/08
12:27
12/08/19
12:27
Hot Stocks
Kura Oncology announces updates for lead drug candidate tipifarnib »

Kura Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PTLA

Portola Pharmaceuticals

$29.22

0.86 (3.03%)

12:24
12/08/19
12/08
12:24
12/08/19
12:24
Hot Stocks
Portola presents interim results from Phase 2a study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.